Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Free Report)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.48 and traded as low as $1.03. Eagle Pharmaceuticals shares last traded at $1.30, with a volume of 940 shares changing hands.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on Eagle Pharmaceuticals in a report on Thursday. They issued a “hold” rating on the stock.
Eagle Pharmaceuticals Price Performance
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Planning purchased a new position in Eagle Pharmaceuticals during the 3rd quarter worth $59,000. Jane Street Group LLC purchased a new position in Eagle Pharmaceuticals during the 3rd quarter worth $96,000. DGS Capital Management LLC grew its stake in Eagle Pharmaceuticals by 44.9% during the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after buying an additional 22,239 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Eagle Pharmaceuticals during the 3rd quarter worth $453,000. Finally, RBF Capital LLC grew its stake in Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after buying an additional 14,991 shares during the last quarter. 85.36% of the stock is currently owned by hedge funds and other institutional investors.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.
Further Reading
- Five stocks we like better than Eagle Pharmaceuticals
- When to Sell a Stock for Profit or Loss
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- What Are the U.K. Market Holidays? How to Invest and Trade
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- How to Profit From Growth Investing
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.